Literature DB >> 17876881

Risk factors for lymph node metastasis and evaluation of reasonable surgery for early gastric cancer.

Ying-Ying Xu1, Bao-Jun Huang, Zhe Sun, Chong Lu, Yun-Peng Liu.   

Abstract

AIM: To give the evidence for rationalizing surgical therapy for early gastric cancer with different lymph node status.
METHODS: A series of 322 early gastric cancer patients who underwent gastrectomy with more than 15 lymph nodes retrieved were reviewed in this study. The rate of lymph node metastasis was calculated. Univariate and multivariate analyses were performed to evaluate the independent factors for predicting lymph node metastasis.
RESULTS: No metastasis was detected in No.5, 6 lymph nodes (LN) during proximal gastric cancer total gastrectomy, and in No.10, 11p, 11d during for combined resection of spleen and splenic artery and in No.15 LN during combined resection of transverse colon mesentery. No.11p, 12a, 14v LN were proved negative for metastasis. The global metastastic rate was 14.6% for LN, 5.9% for mucosa, and 22.4% for submucosa carcinoma, respectively. The metastasis in group II was almost limited in No.7, 8a LN. Multivariate analysis identified that the depth of invasion, histological type and lymphatic invasion were independent risk factors for LN metastasis. No metastasis from distal cancer (<or=1.0 cm in diameter) was detected in group II LN. The metastasis rate increased significantly when the diameter exceeded 3.0 cm. All tumors (<or=1.0 cm in diameter) with LN metastasis and mucosa invasion showed a depressed macroscopic type, and all protruded carcinomas were >3.0 cm in diameter.
CONCLUSION: Segmental/subtotal gastrectomy plus D1/D1+No.7 should be performed for carcinoma (<or=1.0 cm in diameter, protruded type and mucosa invasion). Subtotal gastrectomy plus D2 or D2+No.7, 8a, 9 is the most rational operation, whereas No.11p, 12a, 14v lymphadenectomy should not be recommended routinely for poorly differentiated and depressed type of submucosa carcinoma (>3.0 cm in diameter). Total gastrectomy should not be performed in proximal, so does combined resection or D2+/D3 lymphadenectomy.

Entities:  

Mesh:

Year:  2007        PMID: 17876881      PMCID: PMC4434645          DOI: 10.3748/wjg.v13.i38.5133

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  Prophylactic lymph node dissection for early gastric cancer invading submucosa.

Authors:  Yoichi Ikeda; Motonori Saku; Hirofumi Kawanaka; Michiyasu Nonaka; Kohji Yoshida; Yoshihiko Maehara; Keizo Sugimachi
Journal:  Hepatogastroenterology       Date:  2004 May-Jun

2.  Appropriate gastric resection with lymph node dissection for early gastric cancer.

Authors:  F Borie; N Plaisant; B Millat; J M Hay; P L Fagniez
Journal:  Ann Surg Oncol       Date:  2004-04-12       Impact factor: 5.344

3.  [Review and choice for gastric cancer expanded operation or gastric cancer shrink operation].

Authors:  Jun-qing Chen
Journal:  Zhonghua Wei Chang Wai Ke Za Zhi       Date:  2006-01

4.  Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study.

Authors:  Franco Roviello; Simone Rossi; Daniele Marrelli; Corrado Pedrazzani; Giovanni Corso; Carla Vindigni; Paolo Morgagni; Luca Saragoni; Giovanni de Manzoni; Anna Tomezzoli
Journal:  J Surg Oncol       Date:  2006-09-15       Impact factor: 3.454

5.  Is D2 lymph node dissection necessary for early gastric cancer?

Authors:  Takaki Yoshikawa; Akira Tsuburaya; Osamu Kobayashi; Motonori Sairenji; Hisahiko Motohashi; Yoshikazu Noguchi
Journal:  Ann Surg Oncol       Date:  2002-05       Impact factor: 5.344

6.  Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers.

Authors:  Takuji Gotoda; Akio Yanagisawa; Mitsuru Sasako; Hiroyuki Ono; Yukihiro Nakanishi; Tadakazu Shimoda; Yo Kato
Journal:  Gastric Cancer       Date:  2000-12       Impact factor: 7.370

7.  Extended lymphadenectomy (D2) in patients with early gastric cancer.

Authors:  D Nitti; A Marchet; E Mammano; A Ambrosi; C Belluco; R Mencarelli; M Maino; G Marconato; F Farinati; M Lise
Journal:  Eur J Surg Oncol       Date:  2005-10       Impact factor: 4.424

8.  Indications of a minimized scope of lymphadenectomy for submucosal gastric cancer.

Authors:  Shouji Shimoyama; Hidemitsu Yasuda; Kenichi Mafune; Michio Kaminishi
Journal:  Ann Surg Oncol       Date:  2002-08       Impact factor: 5.344

9.  Indications of limited surgery for gastric cancer with submucosal invasion--analysis of 715 cases with special reference to site of the tumor and level 2 lymph nodes.

Authors:  Takaki Yoshikawa; Akira Tsuburaya; Osamu Kobayashi; Motonori Sairenji; Hisahiko Motohashi; Yoshikazu Noguchi
Journal:  Hepatogastroenterology       Date:  2003 Sep-Oct

10.  Prognostic factors and rational approach in the treatment of submucosal cancer of the stomach.

Authors:  H Kubota; H Tabara; T Kotoh; D D Kumar; N Monden; R Watanabe; H Kohno; N Nagasue
Journal:  J Surg Res       Date:  1998-12       Impact factor: 2.192

View more
  15 in total

1.  Segmental gastrectomy with radical lymph node dissection for early gastric cancer.

Authors:  Takeru Matsuda; Kunihiko Kaneda; Manabu Takamatsu; Keishi Aishin; Masahide Awazu; Akiko Okamoto; Katsunori Kawaguchi
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

Review 2.  Redefining early gastric cancer.

Authors:  Savio G Barreto; John A Windsor
Journal:  Surg Endosc       Date:  2015-04-01       Impact factor: 4.584

3.  CT radiomics nomogram for the preoperative prediction of lymph node metastasis in gastric cancer.

Authors:  Yue Wang; Wei Liu; Yang Yu; Jing-Juan Liu; Hua-Dan Xue; Ya-Fei Qi; Jing Lei; Jian-Chun Yu; Zheng-Yu Jin
Journal:  Eur Radiol       Date:  2019-08-29       Impact factor: 5.315

4.  Apparent Diffusion Coefficient Histogram Analysis for Assessing Tumor Staging and Detection of Lymph Node Metastasis in Epithelial Ovarian Cancer: Correlation with p53 and Ki-67 Expression.

Authors:  Feng Wang; Yuxiang Wang; Yan Zhou; Congrong Liu; Dong Liang; Lizhi Xie; Zhihang Yao; Jianyu Liu
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

5.  Significance of the lymph nodes in the 7th station in rational dissection for metastasis of distal gastric cancer with different T categories.

Authors:  Wu Song; Yulong He; Shaochuan Wang; Weiling He; Jianbo Xu
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

6.  Clinicopathological features associated with lymph node metastasis in early gastric cancer: analysis of a single-institution experience in China.

Authors:  Lizong Shen; Yiming Huang; Maocai Sun; Hao Xu; Wei Wei; Wenxi Wu
Journal:  Can J Gastroenterol       Date:  2009-05       Impact factor: 3.522

7.  Risk factors associated with splenic hilar lymph node metastasis in patients with advanced gastric cancer in northwest China.

Authors:  Zhenqiang Sun; Qisan Wang; Xianbo Yu; Chunlin Ou; Lizhong Yao; Kun Liu; Lin Liu; Lei Ge; Fa Fang; Zeliang Zhao; Haijiang Wang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  Predicting lymph node status in patients with early gastric carcinoma using double contrast-enhanced ultrasonography.

Authors:  Nianyu Xue; Pintong Huang; Wilbert S Aronow; Zongmin Wang; Chandra K Nair; Zhiqiang Zheng; Xuedong Shen; Yimei Yin; Fuguang Huang; David Cosgrove
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

9.  MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1.

Authors:  Y Xu; F Zhao; Z Wang; Y Song; Y Luo; X Zhang; L Jiang; Z Sun; Z Miao; H Xu
Journal:  Oncogene       Date:  2011-08-08       Impact factor: 9.867

10.  Risk factors for No. 12p and No. 12b lymph node metastases in advanced gastric cancer in China.

Authors:  Ji-Feng Feng; Ying Huang; Jing Liu; Huang Liu; Hua-Ying Sheng; Wei-Tian Wei; Wei-Shan Lu; Da-Feng Chen; Wen-You Chen; Xing-Ming Zhou
Journal:  Ups J Med Sci       Date:  2012-10-08       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.